CombiMatrix miscarriage analysis testing now offered by LI Path

May 16, 2014

CombiMatrix Corporation, a molecular diagnostics company specializing in DNA-based testing services for developmental disorders and cancer diagnostics, announced that Long Island Pathology (LI Path) is now offering its patients CombiMatrix's chromosomal microarray analysis (CMA) testing for miscarriage analysis. LI Path, based in East Setauket, New York, is a physician-led diagnostic pathology laboratory serving the New York, New Jersey, and northeastern Pennsylvania areas. Gynecologic pathology is one of LI Path's specialties.

“Patients are becoming much more advanced in their knowledge and awareness of how genetic testing can provide them important information about their pregnancies, and we are very excited to be able to offer CMA testing to help them understand the potential genetic cause of a failed pregnancy and factors for their continued efforts,” says Hal Rose, Managing Partner of LI Path.

Miscarriage analysis testing, also called Products of Conception testing, is a subset of the overall prenatal testing market. It allows OB/GYN physicians and clinicians to better determine if there is a genetic cause for a miscarriage or other related event.

“Miscarriage analysis is a rapidly growing testing market and, as in other areas of prenatal genetic analysis, microarray analysis is becoming the standard of care,” says CombiMatrix President and CEO Mark McDonough. Read more about CMA testing.

Read more